Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Saturday. The firm issued a sell rating on the stock.

Bio-Path Stock Down 7.6 %

Shares of BPTH opened at $0.17 on Friday. The business’s 50 day simple moving average is $0.84 and its 200-day simple moving average is $0.93. Bio-Path has a 1 year low of $0.12 and a 1 year high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.